Literature DB >> 2204724

Regulated expression of nuclear genes by T3 RNA polymerase and lac repressor, using recombinant vaccinia virus vectors.

D Rodriguez1, Y W Zhou, J R Rodriguez, R K Durbin, V Jimenez, W T McAllister, M Esteban.   

Abstract

Recombinant vaccinia viruses that express the bacteriophage T3 RNA polymerase (VV-T3pol) or the Escherichia coli lac repressor (VV-lacI) under control of the early-late vaccinia promoter P7.5 were constructed. To determine whether phage polymerase and lac repressor can function in the nucleus of mammalian cells, the bacterial chloramphenicol acetyltransferase (CAT) gene was cloned downstream of a T3 promoter (PT3-CAT) or downstream of a T3 promoter-lac operator fusion element (PT3Olac-CAT), and these reporter gene cassettes were introduced stably into NIH 3T3 or Ltk- cells. Infection of 3T3/PT3-CAT or Ltk-/PT3-CAT cells by VV-T3pol led to rapid expression of CAT (greater than 20 ng of CAT protein per 10(6) cells). The presence of hydroxyurea (which blocks virus DNA replication) did not prevent CAT production. When 3T3/PT3Olac-CAT cells were infected with both VV-T3pol and VV-lacI (multiplicities of infection of 2.5 and 10, respectively), greater than 30-fold repression of CAT gene activity by lac repressor was observed. This could be reversed to unrepressed levels by the presence of 10 mM o-nitrophenyl-beta-D-galactoside (IPTG) in the medium. Regulated expression of the target gene was observed with cell lines that had been maintained for over 1 year (greater than 50 passages in culture), and Southern blot analysis revealed the presence of the CAT gene only in the nuclear fraction in these cells, demonstrating the stability of the target gene. These results indicate that vaccinia virus-encoded proteins can function in the mammalian nucleus and provide the basis for a genetic system in which essential vaccinia virus genes, placed in the chromosome of a cell, can be used to complement defective virus particles. This approach may prove useful for other virus systems.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2204724      PMCID: PMC247974     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

1.  Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.

Authors:  T R Fuerst; E G Niles; F W Studier; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

2.  The inducible lac operator-repressor system is functional in mammalian cells.

Authors:  M C Hu; N Davidson
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

3.  Regulation of coliphage T3 and T7 RNA polymerases by the lac repressor-operator system.

Authors:  T J Giordano; U Deuschle; H Bujard; W T McAllister
Journal:  Gene       Date:  1989-12-14       Impact factor: 3.688

4.  Nucleosomes inhibit the initiation of transcription but allow chain elongation with the displacement of histones.

Authors:  Y Lorch; J W LaPointe; R D Kornberg
Journal:  Cell       Date:  1987-04-24       Impact factor: 41.582

5.  Inhibitory effect of interferon on the genetic and oncogenic transformation by viral and cellular genes.

Authors:  M Perucho; M Esteban
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

6.  Gene-transfer, stability, and biochemical properties of animal cells transformed with vaccinia DNA.

Authors:  A Pellicer; M Esteban
Journal:  Virology       Date:  1982-10-30       Impact factor: 3.616

7.  Replication of vaccinia DNA in mouse L cells. IV. Protein synthesis and viral DNA replication.

Authors:  M Esteban; J A Holowczak
Journal:  Virology       Date:  1978-05-15       Impact factor: 3.616

8.  Generation of a dominant 8-MDa deletion at the left terminus of vaccinia virus DNA.

Authors:  E Paez; S Dallo; M Esteban
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

9.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

10.  Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques.

Authors:  S Chakrabarti; K Brechling; B Moss
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

View more
  6 in total

1.  Recombinant vaccinia viruses. Design, generation, and isolation.

Authors:  C C Broder; P L Earl
Journal:  Mol Biotechnol       Date:  1999-12-15       Impact factor: 2.695

2.  Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen.

Authors:  O Bruña-Romero; G González-Aseguinolaza; J C Hafalla; M Tsuji; R S Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

Review 3.  Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

Authors:  B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

4.  The major core protein P4a (A10L gene) of vaccinia virus is essential for correct assembly of viral DNA into the nucleoprotein complex to form immature viral particles.

Authors:  R Heljasvaara; D Rodríguez; C Risco; J L Carrascosa; M Esteban; J R Rodríguez
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria.

Authors:  S Li; M Rodrigues; D Rodriguez; J R Rodriguez; M Esteban; P Palese; R S Nussenzweig; F Zavala
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

6.  Association of mouse fibrinogen-like protein with murine hepatitis virus-induced prothrombinase activity.

Authors:  R L Parr; L Fung; J Reneker; N Myers-Mason; J L Leibowitz; G Levy
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.